Novocure Shares Slide After TRIDENT Phase 3 Misses Primary Endpoint
Novocure shares fell sharply in pre-market trading after the company disclosed that its Phase 3 TRIDENT trial did not achieve a statistically significant improvement in overall survival for newly diagnosed glioblastoma patients. The closely watched study showed nearly identical median survival between the trial arms, a development that removes a po…